Cardiovascular diseases (CVDs) continue to be the leading cause of mortality worldwide, with an estimated 17.9 million deaths in 2019, representing 32% of all global deaths. Heart attacks and strokes accounted for approximately 85% of these fatalities The prevalence of CVDs is worsened by metabolic diseases, particularly diabetes, which affects about 422 million people globally, primarily in low- and middle-income countries, and causes 1.5 million deaths annually. Early detection and intervention of CVDs and metabolic diseases are crucial, as many cases can be prevented by addressing modifiable behavioral risk factors such as tobacco use, unhealthy diet, obesity, physical inactivity, and harmful alcohol consumption. Significant advancements in treatment, from pharmacological developments to both invasive and non-invasive techniques, are continuously being made. Given the complexity and clinical significance of this topic, Biomedicines is proud to present a Special Issue titled "Cardiovascular and Metabolic Disease: New Treatments and Future Directions 2.0". This issue aims to compile contemporary scientific information on emerging treatments for CVDs and metabolic diseases. They provide valuable insights to the field and enhance our understanding of these interconnected health challenges.

This book is included in DOAB.